Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of Post-tetanic Count on Subsequent Train-of-four During Recovery From Rocuronium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01086176
Recruitment Status : Completed
First Posted : March 12, 2010
Last Update Posted : April 27, 2010
Sponsor:
Information provided by:
Maisonneuve-Rosemont Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to see how long does the effect of a post-tetanic facilitation last on subsequent train-of-four. The investigators hypothesis is that the effect last at least 30 minutes.

Condition or disease Intervention/treatment
Post-tetanic Count on One Arm, the Other Arm is the Control Device: NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 22 participants
Observational Model: Case-Control
Time Perspective: Prospective
Study Start Date : March 2010
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patient-control Device: NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)
on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The difference at 30 minutes after the post-tetanic count between the TOF% in both arms, we expect a difference of more than 10%

Secondary Outcome Measures :
  1. The difference at 30 minutes after the post-tetanic count on the T1% (of the calibrated T1) in both arms, we expect a difference of more than 10%
  2. The difference of the slope of recuperation on TOF and T1% after a post-tetanic count vs the control arm that had no tetanic stimulation

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Poeple having general anesthesia at HMR
Criteria

Inclusion Criteria:

  • Patient having general anesthesia in dorsal decubitus with both arm available for at least an hour and a half

Exclusion Criteria:

  • Age >75 or <18
  • Neuromuscular disease
  • difficult laryngoscopy predicted
  • Allergy to rocuronium
  • Malignant hyperthermia
  • Full stomach
  • Drugs the influence neuromuscular blockers
  • Decision of the clinician to exclude his patient
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01086176


Locations
Layout table for location information
Canada, Quebec
Hopital Maisonneuve-Rosemont
Montréal, Quebec, Canada, H1T 2M4
Sponsors and Collaborators
Maisonneuve-Rosemont Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Louis-Philippe Fortier MD Msc, HMR
ClinicalTrials.gov Identifier: NCT01086176    
Other Study ID Numbers: MaisonneuveRH-09092
First Posted: March 12, 2010    Key Record Dates
Last Update Posted: April 27, 2010
Last Verified: March 2010